Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 225

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors

LANDIN, K., TENGBORN, L., SMITH, U. · 1991 · Journal of Internal Medicine

Abstract

Insulin resistance and hyperinsulinaemia may play an important role in both the development of hypertension and its accompanying metabolic aberrations. In order to investigate this possibility, nine non‐obese, non‐diabetic, non‐smoking, middle‐aged men with untreated hypertension were treated with metformin 850 mg b.i.d. for 6 weeks as a pilot study and within‐patient comparison. Metformin decreased total and LDL‐cholesterol (P< 0.01), triglyceride (P< 0.01), fasting plasma insulin (P< 0.01) and C‐peptide levels (P< 0.02). Glucose disposal, an indicator of insulin action measured by means of the euglycaemic clamp technique, increased (P< 0.001). Tissue plasminogen activator (t‐PA) activity increased (P< 0.02), and t‐PA antigen decreased (P< 0.01), whereas plasminogen activator inhibitor (PAI‐1) and fibrinogen were unaffected by metformin treatment. Body weight remained unchanged. Withdrawal of metformin was associated with the return of both blood pressure and metabolism towards the initial levels. In conclusion, metformin treatment increased insulin action, lowered blood pressure, improved the metabolic risk factor profile and tended to increase the fibrinolytic activity in these mildly hypertensive subjects. These results support the view that insulin resistance plays a role in hypertension, and may open up a new field for the alleviation of abnormalities associated with cardiovascular disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2796.1991.tb00328.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 225

Metadata

Authors
LANDIN, K., TENGBORN, L., & SMITH, U.
Venue
Journal of Internal Medicine
Publisher
Wiley
Published
1991-02
Volume
229
Issue
2
Pages
181-187
ISSN
  • 0954-6820 (ISSN-L)
  • 1365-2796
OpenAlex
W1997037157
Cited by
225
References
2
FWCI
9.32
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. https://app.cochat.ai/papers/10.1111/j.1365-2796.1991.tb00328.x
The paper
LANDIN, K., TENGBORN, L., & SMITH, U. (1991). Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. Journal of Internal Medicine. https://doi.org/10.1111/j.1365-2796.1991.tb00328.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.